Latest BRAF Stories
The Jeffrey Epstein VI Foundation backs the FDA's landmark decision to approve inhibitor cocktails for melanoma. NEW YORK, Feb.
Introducing CE-IVD marked kits with expanded mutation coverage in colorectal cancer for Kras, Nras, and Braf genes. Tarzana, Calif (PRWEB) January 29, 2014
DURHAM, N.C. and ALISO VIEJO, Calif., Jan. 28, 2014 /PRNewswire/ -- bioMerieux, Inc.
A team of scientists from the University of Leicester has demonstrated a novel treatment for Hairy Cell Leukaemia (HCL), a rare type of blood cancer, using a drug administered to combat skin cancer.
A recently-published study in the journal Clinical Cancer Research supported by the Stand Up To Cancer (SU2C) charitable foundation has identified new molecular targets which could potentially result in new remedies for difficult-to-treat melanomas.
Researchers from UCLA's Jonsson Comprehensive Cancer Center led an international team of scientists in conducting two studies that provide critical insights into two important ways that tumors resist BRAF inhibitors.
- An armed gangster.